Elongation Factor 2 Kinase
"Elongation Factor 2 Kinase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A monomeric calcium-calmodulin-dependent protein kinase subtype that specifically phosphorylates PEPTIDE ELONGATION FACTOR 2. The enzyme lacks a phosphorylatable activation domain that can respond to CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE, however it is regulated by phosphorylation by PROTEIN KINASE A and through intramolecular autophosphorylation.
| Descriptor ID |
D054736
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.125.425 D12.644.360.100.425 D12.776.476.100.425
|
| Concept/Terms |
Elongation Factor 2 Kinase- Elongation Factor 2 Kinase
- Protein Kinase CPK3
- Kinase CPK3, Protein
- Calcium-Calmodulin-Dependent Protein Kinase Type 3
- Calcium Calmodulin Dependent Protein Kinase Type 3
- Eukaryotic Elongation Factor-2 Kinase
- Eukaryotic Elongation Factor 2 Kinase
- CAM Kinase III
- Cam PK III
- E-2 Kinase
- E 2 Kinase
- eEF-2-Specific Ca and Calmodulin-Dependent Protein Kinase III
- eEF 2 Specific Ca and Calmodulin Dependent Protein Kinase III
- Calmodulin-Dependent Protein Kinase III
- Calmodulin Dependent Protein Kinase III
- EF-2 Kinase
- EF 2 Kinase
- Kinase, EF-2
|
Below are MeSH descriptors whose meaning is more general than "Elongation Factor 2 Kinase".
Below are MeSH descriptors whose meaning is more specific than "Elongation Factor 2 Kinase".
This graph shows the total number of publications written about "Elongation Factor 2 Kinase" by people in this website by year, and whether "Elongation Factor 2 Kinase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Elongation Factor 2 Kinase" by people in Profiles.
-
Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: homology modeling, molecular docking, and molecular dynamics simulation. J Biomol Struct Dyn. 2022; 40(24):13355-13365.
-
miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K. Anticancer Agents Med Chem. 2022; 22(14):2607-2618.
-
Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies. Bioorg Chem. 2021 11; 116:105296.
-
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Cell Death Dis. 2021 07 10; 12(7):693.
-
Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer. Cell Signal. 2021 05; 81:109938.
-
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target. J Mol Med (Berl). 2020 06; 98(6):775-787.
-
Delivery of Small Molecule EF2 Kinase Inhibitor for Breast and Pancreatic Cancer Cells Using Hyaluronic Acid Based Nanogels. Pharm Res. 2020 Mar 04; 37(3):63.
-
Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors. J Chem Inf Model. 2020 03 23; 60(3):1766-1778.
-
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
-
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 2018 10; 124:31-39.